Ovarian Cancer Patients Treated with Erythropoietin-Stimulating Agents Have Increased Risk of Cancer Recurrence and Death

The News:

This month at the Society of Gynecologic Oncologists’ Annual Meeting on Women’s Cancer MedPage Today reported that data were presented from a study which showed that in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs) cancer recurrence and death occurred significantly more often.

IDIS Related Question:

Locate recent review articles about an increased risk of cancer recurrence in patients with cancer-related anemia treated with ESAs (epoetin or darbepoetin)?

IDIS Search:

Drug(s): "EPOETIN 20040002" or "DARBEPOETIN ALFA 20040006"

Disease(s): "ANEMIA, NEOPLASM RELATED 285.22"

Descriptor(s): "SIDE EF NEOPLASM CYST 76" and review

IDIS Results:

IDIS Articles 625024 , 613426, and 610066